Details of HTA journal title
Research type: |
HTA Technology Assessment Report |
Title (lead author) etc: |
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review (Shyangdan) 116 pages, Volume 15, number 38 |
DOI |
10.3310/hta15380 |
View/print executive summary
View/print abstract
View full text in pdf format (995 KB)
Go to our correspondence page to comment on this publication
|
|
Headline: |
Study finds that the insulin-sensitiser pioglitazone, as a treatment for non-alcoholic fatty liver disease (NAFLD), shows some improvements in liver histology and other parameters but the newer agents, the glucagon-like peptide-1 analogues, may be more worthy of future trials. The review suggests that the non-alcoholic steatohepatitis stage of NAFLD is most in need of drug trials. |
This report should be referenced as follows: |
Shyangdan D, Clar C, Ghouri N, Henderson R, Gurung T, et al. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. Health Technol Assess 2011;15(38). |
Project ref: |
09/16/01 |
Original project title: |
Insulin sensitizers in treatment of non-alcoholic fatty liver disease |
Chief Investigator: |
Aberdeen HTA Group, University of Aberdeen |
Start Date: |
March 2010 |
Date of publication in HTA journal series |
November 2011 |
Cost: |
This project was commissioned by the HTA programme on a call-off contract basis. |
Project Protocol: |
Project protocol (pdf format, 41 kbytes) |
Printed copies of this title despatched: |
92 (Figures relate to the previous calendar month) |
URL of this page: |
http://www.hta.ac.uk/2288 |
News feeds